BRIEF-Hutchmed (China) Updates FY25 Guidance For Oncology/Immunology Consol Rev To $270M - $350M

Reuters
Aug 07
BRIEF-Hutchmed (China) Updates FY25 Guidance For Oncology/Immunology Consol Rev To $270M - $350M

Aug 7 (Reuters) - HUTCHMED (China) Ltd 0013.HK:

  • UPDATES FY25 GUIDANCE FOR ONCOLOGY/IMMUNOLOGY CONSOL REVENUE TO $270 MILLION - $350 MILLION

Further company coverage: 0013.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10